KYMR — Kymera Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.99bn
- $8.30bn
- $39.21m
Kymera Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Brief: Kymera Therapeutics Q2 EPS USD -0.62
Brief: Kymera Therapeutics Appoints Terence Rooney, MD, As Chief Medical Officer
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology
U.S. STOCKS ON THE MOVE-American Express, Deckers, Q32 Bio
U.S. STOCKS ON THE MOVE-American Express, Deckers, Q32 Bio
RBC downgrades Kymera Therapeutics to 'sector perform,' raises PT
U.S. RESEARCH ROUNDUP-American Tower, H.B. Fuller Company, TD Synnex
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
Kymera jumps on accelerated trial timeline for experimental eczema drug
U.S. STOCKS ON THE MOVE-Wendy's, Canadian Solar, Bio-Techne
Kymera rises on accelerated trial timeline for experimental eczema drug
Brief: Kymera Therapeutics Completes Enrollment In The Phase 2B Broaden2 Trial Of KT-621 In Atopic Dermatitis With Topline Data By Year-End 2026
Brief: Kymera Therapeutics Appoints Felix J. Baker, Ph.D., As Chairman Of The Board Of Directors
Brief: Kymera Therapeutics Announces First Participant Dosed In Phase 1 Trial Of Oral Irak4 Degrader, KT-485, And Milestone Achievement Under Sanofi Collaboration
Brief: Kymera Therapeutics Announces Presentations On KT-621, A First-In-Class, Oral Stat6 Degrader, At The Society For Investigative Dermatology And American Thoracic Society Congresses